CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 
 

RVMD's Net Cash Flow Growth by Quarter and Year

Revolution Medicines Inc 's Net Cash Flow results by quarter and year




RVMD Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -17.53 -20.00 39.40
III Quarter September -22.13 73.16 -66.45 40.90
II Quarter June -46.04 8.11 -156.00 -157.82
I Quarter March 265.81 -10.83 247.33 166.01
FY   197.64 52.91 4.88 88.49



RVMD Net Cash Flow third quarter 2023 Y/Y Growth Comment
Revolution Medicines Inc in the third quarter 2023 recorded net cash outflow of $ -22.13 millions.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Net Cash Flow growth. While Revolution Medicines Inc ' s Net Cash Flow no change of % ranks overall at the positon no. 298 in the third quarter 2023.




RVMD Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - 48.99 % -
FY   - 984.22 % -94.49 % -

Financial Statements
Revolution Medicines Inc 's third quarter 2023 Net Cash Flow $ -22.13 millions RVMD's Income Statement
Revolution Medicines Inc 's third quarter 2022 Net Cash Flow $ 73.16 millions Quarterly RVMD's Income Statement
New: More RVMD's historic Net Cash Flow Growth >>


RVMD Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -3.67 %
III Quarter September - 802.1 % - -
II Quarter June - - - -
I Quarter March - - 527.74 % -
FY (Year on Year)   - 984.22 % -94.49 % -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #56
Overall #298

Net Cash Flow Y/Y Growth Statistics
High Average Low
983.88 % 81.01 % -249.16 %
(Dec 31 2022)   (Mar 31 2022)
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #56
Overall #298
Net Cash Flow Y/Y Growth Statistics
High Average Low
983.88 % 81.01 % -249.16 %
(Dec 31 2022)   (Mar 31 2022)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Revolution Medicines Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Net Cash Flow Comment
Although Revolution Medicines Inc in the III. Quarter 2023 showed net cash outflow of $ -22.13 millions, some analyst said, that those numbers show slight up side compare to the -46.04 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Net Cash Flow growth. While Revolution Medicines Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RVMD's III. Quarter Q/Q Net Cash Flow Comment
Even if Revolution Medicines Inc in the III. Quarter 2023 revealed net cash outflow of $ -22.13 millions, management said, that this point to slight up side relative to the -46.04 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved highest sequential Net Cash Flow growth. While Revolution Medicines Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Revolution Medicines Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ 180.11 $ 275.41 $ 329.56 $ 52.92 $ 50.44
Y / Y Net Cash Flow Growth (TTM) 257.08 % - - 983.88 % -21.53 %
Year on Year Net Cash Flow Growth Overall Ranking # 342 # 270 # 297 # 347 # 0
Seqeuential Net Cash Flow Change (TTM) -34.6 % -16.43 % 522.8 % 4.91 % -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 340 # 230 # 262 # 346 # 0




Cumulative Net Cash Flow growth Comment
Revolution Medicines Inc saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 257.08% year on year, to $ 180 millions if the fiscal year would have ended in Sep 30 2023.
Revolution Medicines Inc 's trailing twelve months Net Cash Flow growth was higher than company's average 81.01% and higher than % growth in Jun 30 2023.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 270 to 342.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
983.88 %
81.01 %
-249.16 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 60
Overall # 342

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
983.88 %
81.01 %
-249.16 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 60
S&P 500 # 340
Cumulative Net Cash Flow growth Comment
Revolution Medicines Inc saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 257.08% year on year, to $ 180 millions if the fiscal year would have ended in Sep 30 2023.
Revolution Medicines Inc 's trailing twelve months Net Cash Flow growth was higher than company's average 81.01% and higher than % growth in Jun 30 2023.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 270 to 342.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
983.88 %
81.01 %
-249.16 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 60
Overall # 342

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
983.88 %
81.01 %
-249.16 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 60
S&P 500 # 340




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
RVMD's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for RVMD's Competitors
Net Cash Flow Growth for Revolution Medicines Inc 's Suppliers
Net Cash Flow Growth for RVMD's Customers

You may also want to know
RVMD's Annual Growth Rates RVMD's Profitability Ratios RVMD's Asset Turnover Ratio RVMD's Dividend Growth
RVMD's Roe RVMD's Valuation Ratios RVMD's Financial Strength Ratios RVMD's Dividend Payout Ratio
RVMD's Roa RVMD's Inventory Turnover Ratio RVMD's Growth Rates RVMD's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Nascent Biotech Inc-4.04%$ -4.038 millions
Halozyme Therapeutics Inc -5.63%$ -5.629 millions
Vystar Corporation-6.05%$ -6.052 millions
Ideaya Biosciences Inc -7.27%$ -7.268 millions
Phibro Animal Health Corporation-7.87%$ -7.874 millions
Luna Innovations Inc-9.06%$ -9.058 millions
Puma Biotechnology Inc -13.53%$ -13.534 millions
Fulgent Genetics Inc -14.21%$ -14.211 millions
Prestige Consumer Healthcare Inc -16.52%$ -16.522 millions
Omniab Inc -20.57%$ -20.566 millions
Gossamer Bio Inc -22.91%$ -22.914 millions
Alnylam Pharmaceuticals Inc -24.60%$ -24.599 millions
Emmaus Life Sciences Inc -26.90%$ -26.904 millions
Kala Bio inc -27.38%$ -27.384 millions
Protara Therapeutics Inc -29.54%$ -29.540 millions
Msa Safety Incorporated-31.72%$ -31.716 millions
Avalo Therapeutics inc -32.14%$ -32.143 millions
Biovie Inc -32.27%$ -32.265 millions
Veracyte inc -32.97%$ -32.966 millions
Coherus Biosciences inc -35.07%$ -35.068 millions
Biomarin Pharmaceutical Inc-35.76%$ -35.762 millions
International Stem Cell Corporation-40.00%$ -40.000 millions
Arvinas Inc -42.82%$ -42.822 millions
89bio Inc -44.85%$ -44.846 millions
Assertio Holdings inc -46.56%$ -46.561 millions
Infusystem Holdings Inc -48.08%$ -48.077 millions
Eqrx Inc -48.96%$ -48.965 millions
Privia Health Group Inc -49.62%$ -49.617 millions
Nektar Therapeutics-49.69%$ -49.693 millions
Avinger Inc -53.79%$ -53.788 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com